ARTICLE | Emerging Company Profile
Myricx: ADCs with a lipidation inhibitor payload
U.K.-based Myricx is turning a small molecule for parasitic diseases into an ADC payload for cancers
December 13, 2023 1:37 AM UTC
Myricx is pioneering a post-translational modification inhibitor of myristoylation as the payload for antibody-drug conjugates.
Myristoylation is a lipid modification involving the addition of myristic acid, a 14-carbon fatty acid, to the N-terminus of proteins, catalyzed by the enzymes NMT1 and NMT2. The modification dictates signal transduction, protein stability and localization of proteins to membranes. About 150 human proteins are myristoylated...
BCIQ Company Profiles
Biocytogen Pharmaceuticals (Beijing) Co. Ltd.